Positioning a herbal product in a foreign market: two open niches and one unclosed evidence gap

The case in brief

The client developed a herbal product in an improved dosage form (a solubilised, self-emulsifying system in a solid capsule) and planned to enter a foreign national market. A team of 4 specialists examined the product across 6 questions. The conclusion came out two-part and honest: the form itself is a strength (it mechanistically increases absorption) and the market niches for it are open; but the main claimed advantage — 'increased bioavailability' — is not confirmed by a single clinical or pharmacokinetic study of this specific formula. The same product concept was already taken to another national market by an outside researcher ~7 years ago — and ran into exactly the same gap. This independent coincidence turned an unwelcome conclusion into a measurable reduction in risk.

The starting situation

The client had prepared the formulation of a herbal product and of its enhanced version (the same core plus a block of neurotropic B-group vitamins) and was weighing entry into a foreign national market and — through a shared registration space — into the markets adjacent to it. The key commercial argument put forward was 'increased bioavailability' thanks to the special form. We were asked to answer not a marketing question but an engineering one: how well founded this claim is scientifically, who already occupies the niche worldwide and in the target market, and exactly what the product would reach the shelf with.

What the analysis showed

We reconstructed the actual formulation from the file provided and examined it on the substance, not the label.

• The form is genuinely a strength — but by mechanism, not by evidence. The active substance : solubiliser ratio is 1:3 (300 mg of a nonionic surfactant per 100 mg of extract): a classic self-emulsifying delivery system, not a liquid and not a tincture. When the capsule dissolves, the mass spontaneously emulsifies and keeps the lipophilic actives in dissolved form. For a comparable self-emulsifying form, a published study showed >90% dissolution already in the stomach's acidic environment, versus effectively zero release for the native extract. So a gain in absorption is expected — but this is an extrapolation from the class of solubiliser.
• The main vulnerability — there is no evidence base for the product's own formula. No direct clinical pharmacokinetic data for the exact pairing 'this extract + this solubiliser (1:3)' was found in the literature. The magnitude of the bioavailability gain for the product itself cannot be stated without its own pharmacokinetic study — the estimate remains mechanistic.
• A map of the global market: improved forms are many, truly bioavailable ones are few. We consolidated 21 global forms and manufacturers (ingredients, phytosomes, micellar and liposomal products, alcohol tinctures) into a single table listing form, solubility and region. The closest bioavailable analogue in a neighbouring market claims a ~3-fold increase in bioavailability versus standard forms — but that is a different chemical carrier and a different market.
• Two open niches in the target market. A solubilised / self-emulsifying form of this herbal substance essentially does not exist in the target market, and the pairing 'this extract + neurotropic B-group vitamins' does not exist at all. The product falls into two simultaneously unoccupied niches at once — this is its main competitive distinction.
• Independent confirmation of the gap. The same product concept ('a solubilised, high-bioavailability extract in a solid capsule with a liquid/emulsified phase') was already taken to another national market by an outside researcher ~7 years ago. Both the strength (the bioavailability technology) and the weakness matched: that analysis explicitly recorded the absence of clinical confirmation for its own formula. Moreover, in that — saturated — market the single-ingredient form sold poorly, and it was precisely the combinations that 'took off': an empirical argument in favour of the enhanced version (extract + B vitamins) rather than the 'pure' single-ingredient product.
• Two discrepancies within the formulation itself. Vitamin B2, declared earlier, is absent from the actual composition of the enhanced version — there is only the neurotropic trio; the application and the composition need to be brought into line. In addition, the formulation does not lock in standardisation against the key active marker — without it the main argument about potency is lost.

The result

The client received not a 'good/bad' verdict but a working map for market entry: the form is a strength, though not yet proven by the product's own data; two niches are open; commercially, the bet is better placed on the combined version than on the single-ingredient product. Alongside this — a prioritised list of what to close before launch: initiate the product's own pharmacokinetic bioavailability study, lock in standardisation against the active marker, reconcile the discrepancy in the vitamin composition, and account for the restrictions on medical claims at registration. A review like this lets you enter a new market with calibrated positioning rather than an unproven slogan.

Caveats and data status

What is measured, what is an estimate, and what comes from the client and the materials provided.

• Measured in the literature: the >90% versus ~0% dissolution refers to a published study of a comparable self-emulsifying form, not to the client's product itself.
• Estimate (extrapolation): the conclusion of increased absorption for the product is mechanistic, based on the class of solubiliser; there is no quantitative bioavailability figure without the product's own pharmacokinetic study.
• From the client and the materials provided: the formulation was reconstructed from the file supplied; the comparison with the outside researcher's conclusion is based on a document provided by the client.
• Market data (the availability of niches, the product range, the ~3-fold increase in the analogue) are dynamic and estimative in nature — a 2025–2026 reference point.

The case is anonymised. The client, the product, the active substance and the country are under NDA; details are discussed in a diagnostic session. The figures are from a real project; market data are estimative in nature, a 2025–2026 reference point. This is not investment, legal or medical advice.